MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Clevudine and Peg-interferon in Sequence Compared With Clevudine Alone in the Patients With HBeAg(+) Chronic Hepatitis B or Clevudine and Peg-interferon Sequential Treatment in Patients With Chronic Hepatitis B Who Have HBeAg(+)

NCT01264367 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-12-18

No results posted yet for this study

Summary

A study to evaluate the efficacy and safety of clevudine and peg-interferon in sequence compared with clevudine alone in the patients with HBeAg(+) chronic Hepatitis B or clevudine and peg-interferon sequential treatment in patients with chronic Hepatitis B who have HBeAg(+)

Conditions

  • HBeAg(+) Chronic Hepatitis B

Interventions

DRUG

Clevudine

30mg,QD

DRUG

Clevudine + Peg-interferon

30mg, QD(for 24 weeks) + 180mcg,QW(for 24 weeks)

Sponsors & Collaborators

  • Bukwang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Lee Chang Don, MD, PhD · The catholic university of korea, Uijeongbu ST.Mary's hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2013-08-31
Completion
2014-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01264367 on ClinicalTrials.gov